J. Rosenberg

发表

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

C. Brennan, M. Ladanyi, M. Berger, 2019, Nature Genetics.

Comprehensive molecular characterization of urothelial bladder carcinoma

Steven J. M. Jones, Evan O. Paull, Joshua M. Stuart, 2014, Nature.

Antibody-Drug Conjugates in Urothelial Carcinomas

J. Rosenberg, M. Sarfaty, 2020, Current Oncology Reports.

Cancer Susceptibility Mutations in Patients With Urothelial Malignancies.

Kenneth Offit, Barry S Taylor, Vignesh Ravichandran, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract Cancer.

T. Powles, N. Agarwal, E. Plimack, 2019, The oncologist.

TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

R. Bourgon, P. Hegde, Yulei N. Wang, 2018, Nature.

Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma

E. V. Van Allen, D. Takeda, T. Choueiri, 2018, British Journal of Cancer.

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

R. Bourgon, P. Hegde, T. Powles, 2017, The Lancet.

Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer

G. Getz, S. Carter, L. Garraway, 2017, Nature Communications.

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

R. Bourgon, T. Powles, M. Galsky, 2016, The Lancet.

Clonal evolution of chemotherapy-resistant urothelial carcinoma

Davide Prandi, Francesca Demichelis, Olivier Elemento, 2016, Nature Genetics.

Somatic ERCC2 Mutations Are Associated with a Distinct Genomic Signature in Urothelial Tumors

Gad Getz, Paz Polak, Eliezer M Van Allen, 2016, Nature Genetics.

Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma

G. Freeman, S. Signoretti, T. Choueiri, 2016, Scientific Reports.

Collaborating to Move Research Forward: Proceedings of the 10th Annual Bladder Cancer Think Tank

M. Galsky, G. Iyer, J. Doroshow, 2016, Bladder cancer.

DNA copy number analysis of metastatic urothelial carcinoma with comparison to primary tumors

M. Meyerson, M. Loda, P. Kantoff, 2015, BMC Cancer.

Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma.

S. Gabriel, G. Getz, P. Kantoff, 2014, Cancer discovery.

Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.

C. Rudin, J. Wolchok, M. Voss, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and safety of nivolumab monotherapy in metastatic urothelial cancer (mUC): Results from the phase I/II CheckMate 032 study.

P. Sharma, P. Ott, J. Rosenberg, 2016 .

Atezolizumab (atezo) in first-line cisplatin-ineligible or platinum-treated locally advanced or metastatic urothelial cancer (mUC): Long-term efficacy from phase 2 study IMvigor210.

A. Balar, J. Rosenberg, D. Petrylak, 2018 .

Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis

M. Vignali, Arun Ahuja, E. Mardis, 2017, PLoS medicine.

Abstract CT115: Phase 1bKEYNOTE 200 (STORM study):A study of an intravenously delivered oncolytic virus, Coxsackievirus A21 in combination with pembrolizumab in advanced cancer patients

C. Rudin, E. Schmidt, A. Melcher, 2017 .

Keynote-200 phase 1b: A novel combination study of intravenously delivered coxsackievirus A21 and pembrolizumab in advanced cancer patients.

C. Rudin, E. Schmidt, H. Pandha, 2017 .

Development of Genome-Derived Tumor Type Prediction to Inform Clinical Cancer Care.

Alexander V Penson, B. Taylor, N. Schultz, 2019, JAMA oncology.

Advanced Urothelial Carcinoma: Overcoming Treatment Resistance through Novel Treatment Approaches

J. Rosenberg, R. Bambury, 2012, Front. Pharmacol..

Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma.

T. Choueiri, M. Atkins, W. Oh, 2011, Urologic oncology.

EV-201: Results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and immune checkpoint inhibitors.

M. Galsky, E. Heath, A. Balar, 2019, Journal of Clinical Oncology.

A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma

V. Weinberg, E. Small, J. Rosenberg, 2011, Cancer.

The high incidence of vascular thromboembolic events in patients with metastatic or unresectable urothelial cancer treated with platinum chemotherapy agents

I. Ostrovnaya, D. Bajorin, E. Zabor, 2016, Cancer.

Integrative Analysis of 1q23.3 Copy-Number Gain in Metastatic Urothelial Carcinoma

W. Hahn, M. Loda, P. Kantoff, 2014, Clinical Cancer Research.

Polygenic risk for skin autoimmunity impacts immune checkpoint blockade in bladder cancer

T. Powles, C. Hammer, I. Mellman, 2020, Proceedings of the National Academy of Sciences.

Polygenic risk for skin autoimmunity impacts immune checkpoint blockade in bladder cancer

T. Powles, C. Hammer, I. Mellman, 2019, Proceedings of the National Academy of Sciences.

Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant: A Multi-institutional Study.

J. Ross, F. Montorsi, A. Salonia, 2020, Clinical genitourinary cancer.

Neoadjuvant Gemcitabine-Cisplatin Plus Radical Cystectomy-Pelvic Lymph Node Dissection for Muscle-invasive Bladder Cancer: A 12-year Experience.

P. Russo, I. Ostrovnaya, G. Iyer, 2020, Clinical genitourinary cancer.

Re: Russell E.N. Becker, Alexa R. Meyer, Aaron Brant, et al. Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.016.

E. V. Van Allen, G. Iyer, B. Bochner, 2020, European urology.

Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates.

P. Kantoff, A. Kibel, S. Signoretti, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.

T. Choueiri, J. Rosenberg, J. Bellmunt, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of Surgery in the Primary Tumor Site for Metastatic Urothelial Cancer: Analysis of an International, Multicenter, Multidisciplinary Database.

F. Montorsi, N. Agarwal, M. Galsky, 2020, European urology oncology.

Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract Cancers.

T. Powles, N. Agarwal, E. Plimack, 2020, European urology oncology.

Update on chemotherapy for advanced bladder cancer.

P. Carroll, E. Small, J. Rosenberg, 2005, The Journal of urology.

Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1-3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3-altered Advanced/Metastatic Urothelial Carcinoma.

M. Galsky, D. Bajorin, J. Rosenberg, 2020, European urology.

Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy.

L. Gordon, M. Czuczman, D. Maloney, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Congestive heart failure risk in patients with breast cancer treated with bevacizumab.

T. Choueiri, H. Burstein, J. Rosenberg, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 2 trial of buparlisib in patients with platinum‐resistant metastatic urothelial carcinoma

M. Berger, E. V. Van Allen, I. Ostrovnaya, 2020, Cancer.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .

Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGFI and IGFII, in Patients with Advanced Solid Tumors

E. Plimack, P. LoRusso, J. Rosenberg, 2014, Clinical Cancer Research.

Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium.

David C. Smith, V. Weinberg, E. Small, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.

M. Michaelson, J. Sosman, B. Rini, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma

L. Mariani, T. Powles, E. Plimack, 2018, The Journal of urology.

Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity.

M. Grever, J. Byrd, I. Flinn, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Venous Thromboembolism Risk in Patients With Locoregional Urothelial Tract Tumors

T. Powles, N. Agarwal, E. Plimack, 2017, Clinical genitourinary cancer.

Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium.

G. Sonpavde, M. Galsky, C. Sternberg, 2010, The Lancet. Oncology.

Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma.

D. Czerwinski, D. Maloney, J. Rosenberg, 1994, Blood.

Suggestions for regulatory agency approval of second-line systemic therapy for metastatic transitional cell carcinoma.

G. Sonpavde, M. Galsky, C. Sternberg, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genitourinary Medical Oncology Expert Opinion Survey Regarding Treatment Management in the COVID-19 Pandemic

R. Motzer, M. Voss, G. Iyer, 2021, Clinical Genitourinary Cancer.

Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma

D. Lamm, G. Sonpavde, M. Galsky, 2017, Journal of Immunotherapy for Cancer.

Long-term Outcomes of Local and Metastatic Small Cell Carcinoma of the Urinary Bladder and Genomic Analysis of Patients Treated With Neoadjuvant Chemotherapy.

V. Reuter, I. Ostrovnaya, B. Weigelt, 2022, Clinical genitourinary cancer.

Ixabepilone, mitoxantrone, and prednisone for metastatic castration‐resistant prostate cancer after docetaxel‐based therapy

David C. Smith, V. Weinberg, E. Small, 2011, Cancer.

Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study.

G. Pond, T. Powles, N. Agarwal, 2017, European urology focus.

Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer

J. Rosenberg, Yasser Rehman, 2012, Drug design, development and therapy.

Novel agents and new therapeutics in castration-resistant prostate cancer

Yichao Wu, J. Rosenberg, M. Taplin, 2011, Current opinion in oncology.

Sunitinib efficacy against advanced renal cell carcinoma.

R. Motzer, M. Michaelson, B. Redman, 2007, The Journal of urology.

The Genitourinary Pathology Society Update on Classification and Grading of Flat and Papillary Urothelial Neoplasia With New Reporting Recommendations and Approach to Lesions With Mixed and Early Patterns of Neoplasia

J. Cheville, R. Shah, J. McKenney, 2021, Advances in anatomic pathology.

“Primary” and “secondary” muscle-invasive bladder cancer is more than just a surrogate for molecular subtypes

G. Iyer, H. Al-Ahmadie, B. Bochner, 2019, Translational cancer research.

Reply to D. Pouessel et al, J.B. Aragon-Ching, and B.A. Adesunloye.

T. Choueiri, E. Plimack, J. Rosenberg, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Refined deletion mapping of the chromosome 19q glioma tumor suppressor gene to the D19S412-STD interval.

D. Louis, H. Mohrenweiser, A. von Deimling, 1996, Oncogene.

IMvigor 210, a phase II trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC).

J. Rosenberg, J. Bellmunt, D. Petrylak, 2016 .

Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF.

B. Kavanagh, E. Small, D. McNeel, 2009, Cancer research.

Treatment Outcomes of Immune-Related Cutaneous Adverse Events.

R. Motzer, G. Fabbrocini, M. Lacouture, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Current status of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer

J. Rosenberg, 2007, Expert review of anticancer therapy.

Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.

T. Powles, P. Albers, H. Nishiyama, 2021, The Lancet. Oncology.

Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma.

J. Rosenberg, M. Teo, 2018, The Urologic clinics of North America.

Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial

P. Sharma, P. Ott, J. Rosenberg, 2016 .

Update in Urothelial Carcinoma: Novel Agents and Targeted Therapy.

J. Rosenberg, E. Guancial, C. Sweeney, 2011, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Efficacy and safety of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (mRCC).

M. Michaelson, J. Sosman, B. Rini, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Incidence and Effect of Thromboembolic Events in Radical Cystectomy Patients Undergoing Preoperative Chemotherapy for Muscle‐invasive Bladder Cancer

Timothy F. Donahue, A. Vickers, D. Sjoberg, 2017, Clinical genitourinary cancer.

A phase II study of the dual MET/VEGFR2 inhibitor XL880 in patients (pts) with papillary renal carcinoma (PRC)

W. Linehan, R. Srinivasan, T. Choueiri, 2007 .

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206.

E. Small, B. Rini, J. Rosenberg, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

New 6-factor prognostic model for patients (pts) with advanced urothelial carcinoma (UC) receiving post-platinum atezolizumab.

G. Pond, T. Powles, T. Choueiri, 2018 .

Utility of Routine Preoperative 18F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography (18F-FDG PET/CT) in Identifying Pathologic Lymph Node Metastases at Radical Cystectomy.

P. D. Di Paolo, H. Vargas, B. Bochner, 2020, The Journal of urology.

Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma?

R. Figlin, R. Townsend, J. Rosenberg, 2016, European journal of cancer.

Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome.

V. Weinberg, E. Small, J. Rosenberg, 2007, The Journal of urology.

The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experience.

J. Chaim, I. Ostrovnaya, M. Voss, 2015, The oncologist.

Targeted sequencing of upper tract urothelial carcinoma.

M. Berger, J. Coleman, G. Iyer, 2014 .

Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial Carcinoma

M. Galsky, D. Bajorin, J. Rosenberg, 2021, Clinical genitourinary cancer.

Trends in Management and Outcomes Among Patients with Urothelial Carcinoma Undergoing Radical Cystectomy from 1995 to 2015: The Memorial Sloan Kettering Experience.

Lucas W. Dean, D. Sjoberg, B. Bochner, 2020, The Journal of urology.

SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer

T. Powles, G. Sonpavde, M. Galsky, 2018, World Journal of Urology.

Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival

T. Powles, N. Agarwal, M. Galsky, 2016, Cancer medicine.

Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma.

P. Albers, T. Choueiri, N. Agarwal, 2014, Clinical genitourinary cancer.

The impact of prior platinum therapy on survival in patients with metastatic urothelial cancer receiving vinflunine

T. Choueiri, J. Rosenberg, J. Bellmunt, 2013, British Journal of Cancer.

A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy.

G. Sonpavde, W. Oh, M. Galsky, 2011, The Lancet. Oncology.

Randomized, double-blind, placebo-controlled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: scientific rationale and study design.

David C. Smith, R. Dunn, J. Rosenberg, 2007, Clinical genitourinary cancer.

Sequencing of PD-1/L1 Inhibitors and Carboplatin-Based Chemotherapy for Cisplatin-Ineligible Metastatic Urothelial Carcinoma.

T. Powles, G. Sonpavde, M. Galsky, 2020, The Journal of urology.

EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees.

W. Oyen, T. H. van der Kwast, M. Babjuk, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Review: Novel agents for advanced bladder cancer

G. Sonpavde, J. Rosenberg, A. Elfiky, 2009, Therapeutic advances in medical oncology.

Relationship between hyperphosphatemia with infigratinib (BGJ398) and efficacy in FGFR3-altered advanced/metastatic urothelial carcinoma (aUC).

M. Galsky, D. Bajorin, J. Rosenberg, 2020 .

M. Galsky, E. Heath, A. Balar, 2022, European urology.

Incomplete Cross-Resistance Between Taxanes for Advanced Urothelial Carcinoma: Implications for Clinical Practice and Trial Design.

G. Pond, T. Choueiri, G. Sonpavde, 2015, Clinical genitourinary cancer.

Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials.

G. Pond, P. Albers, T. Choueiri, 2013, European urology.

Impact of number of lines of prior chemotherapy in patients (pts) with advanced urothelial carcinoma (UC) receiving salvage therapy.

G. Pond, P. Albers, T. Choueiri, 2014 .

Impact of prior platinum agent and site of primary in patients with advanced urothelial carcinoma (UC) receiving salvage therapy.

G. Pond, P. Albers, T. Choueiri, 2014 .

Treatment patterns and outcomes in “real world” patients (pts) with metastatic urothelial cancer (UC).

T. Powles, M. Galsky, J. Rosenberg, 2013 .

The high incidence of vascular thromboembolic events (VTE) in advanced urothelial cancer (UC) patients (pts) treated with carboplatin (Cb): Analysis of treatment with gemcitabine (G)/cb (GCb), gcb/bevacizumab (GCbBev), or gemcitabine/cisplatin (GCis).

I. Ostrovnaya, D. Bajorin, E. Zabor, 2014 .

Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2)

T. Choueiri, G. Sonpavde, M. Regan, 2018, British Journal of Cancer.

Pretreatment Eosinophil Counts in Patients With Advanced or Metastatic Urothelial Carcinoma Treated With Anti-PD-1/PD-L1 Checkpoint Inhibitors

I. Ostrovnaya, G. Iyer, D. Bajorin, 2021, Journal of immunotherapy.

Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma.

T. Powles, G. Sonpavde, J. Rosenberg, 2021, The New England journal of medicine.

Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract Carcinoma.

T. Powles, C. Sternberg, J. Rosenberg, 2020, European urology focus.

Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell‐free DNA results

M. Galsky, D. Bajorin, J. Rosenberg, 2020, Cancer.

EMA and FDA prune the checkpoint inhibitor treatment landscape

J. Rosenberg, M. Teo, 2018, Nature reviews. Urology.

Nomogram to Assess the Survival Benefit of New Salvage Agents for Metastatic Urothelial Carcinoma in the Era of Immunotherapy

G. Pond, T. Choueiri, G. Sonpavde, 2018, Clinical genitourinary cancer.

The Khorana Score in Predicting Venous Thromboembolism for Patients With Metastatic Urothelial Carcinoma and Variant Histology Treated With Chemotherapy

M. Galsky, J. Rosenberg, A. Alva, 2017, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

The Khorana score in predicting venous thromboembolism for metastatic urothelial carcinoma and variant histology patients treated with chemotherapy

M. Galsky, J. Rosenberg, A. Alva, 2017 .

Fundamental immune–oncogenicity trade-offs define driver mutation fitness

A. Levine, J. Wolchok, B. Weigelt, 2022, Nature.

A phase I study of sorafenib and RAD001 for metastatic clear cell renal cell carcinoma.

V. Weinberg, E. Small, J. Rosenberg, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation

Mauro A. A. Castro, A. Lenis, N. Socci, 2022, Nature Communications.

Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206.

E. Small, B. Rini, J. Rosenberg, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A retrospective evaluation of second‐line chemotherapy response in hormone‐refractory prostate carcinoma

W. Oh, M. Galsky, V. Weinberg, 2006, Cancer.

Arterial embolization for the management of gastrointestinal hemorrhage from metastatic renal cell carcinoma.

E. Nakakura, J. Rosenberg, N. Fidelman, 2010, Journal of vascular and interventional radiology : JVIR.

Patterns of Bladder Preservation Therapy Utilization for Muscle-Invasive Bladder Cancer

Ronald C. Chen, M. Galsky, M. Milowsky, 2016, Bladder cancer.

PD-L1 expression, Cancer Genome Atlas (TCGA) subtype, and mutational load as independent predictors of response to atezolizumab (atezo) in metastatic urothelial carcinoma (mUC; IMvigor210).

R. Bourgon, P. Hegde, T. Powles, 2016 .

A double-blind randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated advanced urothelial cancer.

P. Kantoff, T. Choueiri, J. Rosenberg, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Contribution of systemic and somatic factors to clinical response and resistance in urothelial cancer: an exploratory multi-omic analysis

M. Vignali, Arun Ahuja, E. Mardis, 2017, bioRxiv.

Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206.

E. Small, B. Rini, J. Rosenberg, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical and Genomic Characterization of Bladder Carcinomas With Glandular Phenotype.

A. Lenis, V. Reuter, I. Ostrovnaya, 2022, JCO precision oncology.

CALGB 90601 (Alliance): Randomized, double-blind, placebo-controlled phase III trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with metastatic urothelial carcinoma.

M. Morris, J. Rosenberg, K. Ballman, 2019, Journal of Clinical Oncology.

New treatments for patients with progressive metastatic urothelial carcinoma.

J. Rosenberg, 2021, Clinical advances in hematology & oncology : H&O.

Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.

M. Czuczman, D. Maloney, J. Rosenberg, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of Metastatic Extramammary Paget Disease with Combination Ipilimumab and Nivolumab: A Case Report

G. Iyer, D. Bajorin, M. Lacouture, 2021, Case Reports in Oncology.

What is the current status of second-line chemotherapy for castration-resistant prostate cancer?

W. Oh, J. Rosenberg, 2008, Nature Clinical Practice Urology.

A phase II study of the c-Met RTK inhibitor XL880 in patients (pts) with papillary renal-cell carcinoma (PRC)

S. Srinivas, J. Rosenberg, U. Vaishampayan, 2007 .

Genomic heterogeneity as a barrier to precision oncology in urothelial cancer

A. Lenis, M. Berger, I. Ostrovnaya, 2022, Cell reports.

Efficacy of BGJ398, a fibroblast growth factor receptor (FGFR) 1-3 inhibitor, in patients (pts) with previously treated advanced/metastatic urothelial carcinoma (mUC) with FGFR3 alterations.

R. Berger, M. Galsky, D. Bajorin, 2016 .

Branched evolution and intratumor heterogeneity of urothelial carcinoma of the bladder.

M. Berger, G. Iyer, H. Al-Ahmadie, 2014 .

Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer

M. Milowsky, S. Srinivas, J. Rosenberg, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Vinflunine: drug safety evaluation of this novel synthetic vinca alkaloid

T. Choueiri, J. Rosenberg, J. Bellmunt, 2011, Expert opinion on drug safety.

A phase II, single-arm study of AS1411 in metastatic renal cell carcinoma (RCC).

R. Figlin, J. Rosenberg, H. Drabkin, 2010 .

Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis of randomized clinical trials.

T. Choueiri, G. Sonpavde, M. Galsky, 2013, Critical reviews in oncology/hematology.

A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma

E. Small, J. Pérez-Ruixo, J. Rosenberg, 2005, Cancer.

Single Arm Phase I/II Study of Everolimus and Intravesical Gemcitabine in Patients with Primary or Secondary Carcinoma In Situ of the Bladder who failed Bacillus Calmette Guerin (NCT01259063)

D. Sjoberg, B. Bochner, D. Bajorin, 2017, Bladder cancer.

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer

E. Plimack, M. Galsky, A. Balar, 2021, Journal for ImmunoTherapy of Cancer.

Clinical-pathologic stage discrepancy in bladder cancer patients treated with radical cystectomy: results from the national cancer data base.

A. Jemal, A. Kibel, M. Blute, 2014, International journal of radiation oncology, biology, physics.

A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma

L. Garraway, R. Figlin, T. Choueiri, 2014, Investigational New Drugs.

Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma.

M. Czuczman, D. Maloney, J. Rosenberg, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade

P. Hegde, T. Powles, Z. Modrušan, 2020, Nature Medicine.

The biology and rationale of targeting nectin-4 in urothelial carcinoma

E. Heath, J. Rosenberg, 2020, Nature Reviews Urology.

Identification of a Synthetic Lethal Relationship between Nucleotide Excision Repair Deficiency and Irofulven Sensitivity in Urothelial Cancer

Z. Szallasi, S. Brunak, I. Csabai, 2020, Clinical Cancer Research.

NEXT GENERATION SEQUENCING OF NON‐MUSCLE INVASIVE BLADDER CANCER REVEALS POTENTIAL BIOMARKERS AND RATIONAL THERAPEUTIC TARGETS: PD48‐11

N. Schultz, M. Berger, I. Ostrovnaya, 2017, European urology.

Genomic characterization of response to chemoradiation in urothelial bladder cancer

M. Berger, M. Zelefsky, I. Ostrovnaya, 2016, Cancer.

Summary and Recommendations from the National Cancer Institute’s Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer

S. Groshen, C. Tangen, C. Drake, 2016, Bladder cancer.

Genomic Characterization of Upper Tract Urothelial Carcinoma.

N. Schultz, M. Berger, V. Reuter, 2015, European urology.

Molecular events in muscle‐invasive bladder cancer development

Jaegil Kim, William Y. Kim, D. Kwiatkowski, 2015 .

HER2 as a target in invasive urothelial carcinoma

M. Loda, M. Salido, E. Gallardo, 2015, Cancer medicine.

The Role of Genomics in the Management of Advanced Bladder Cancer

J. Rosenberg, E. Guancial, 2015, Current Treatment Options in Oncology.

Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder.

N. Schultz, M. Berger, V. Reuter, 2015, European urology.

Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma.

M. Milowsky, D. Bajorin, C. Sternberg, 2014, European journal of cancer.

Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations.

R. Berger, M. Galsky, D. Bajorin, 2018, Cancer discovery.

Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, phase 1/2 trial

P. Sharma, F. D. De Braud, P. Ott, 2016, The Lancet. Oncology.

Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients

David R. Jones, N. Schultz, M. Ladanyi, 2021, Cell.

LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade

J. Wolchok, R. Shen, G. Iyer, 2021, Science Translational Medicine.

Modeling biological and genetic diversity in upper tract urothelial carcinoma with patient derived xenografts

Jianjiong Gao, A. Hakimi, I. Ostrovnaya, 2020, Nature Communications.

B. Taylor, M. Berger, I. Ostrovnaya, 2018, Clinical Cancer Research.

Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis

N. Socci, B. Taylor, N. Schultz, 2017, Clinical Cancer Research.

Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma

Nana O. Herschend, M. Nielsen, J. Wolchok, 2022, Nature Communications.

Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers.

M. Berger, J. Wolchok, J. Chaim, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nivolumab for the treatment of urothelial cancers

J. Rosenberg, M. Teo, 2018, Expert review of anticancer therapy.

A multifactorial model of T cell expansion and durable clinical benefit in response to a PD-L1 inhibitor

Mark D. M. Leiserson, C. Borgs, J. Chayes, 2017, bioRxiv.

DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma

M. Berger, I. Ostrovnaya, H. Al-Ahmadie, 2017, Clinical Cancer Research.

Multi-omic analysis of urothelial cancer patients treated with PD-L1 blockade demonstrates the contribution of both systemic and somatic factors to the biology of response and resistance

M. Vignali, Arun Ahuja, E. Mardis, 2016 .

Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.

P. Kantoff, E. Small, J. Rosenberg, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Targeting Germline- and Tumor-Associated Nucleotide Excision Repair Defects in Cancer

B. Taylor, M. Berger, C. Rudin, 2020, Clinical Cancer Research.

High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade

P. Hegde, T. Powles, Z. Modrušan, 2020, Nature Medicine.

Global Cancer Transcriptome Quantifies Repeat Element Polarization between Immunotherapy Responsive and T Cell Suppressive Classes

D. Bajorin, J. Rosenberg, D. Ting, 2017, bioRxiv.

Identification of ALK Gene Alterations in Urothelial Carcinoma

P. Kantoff, H. Himmelbauer, M. Salido, 2011, PloS one.

EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma

David C. Smith, E. Plimack, M. Milowsky, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy

M. Galsky, E. Heath, A. Balar, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Novel molecular targets for urothelial carcinoma

J. Rosenberg, B. Faltas, S. Tagawa, 2015, Expert opinion on therapeutic targets.

Functional phenotyping and genotyping of circulating tumor cells from patients with castration resistant prostate cancer.

Emmanuel R. Yera, J. Rosenberg, J. Simko, 2009, Cancer letters.

Bladder cancer: modeling and translation.

W. Hahn, J. Rosenberg, 2009, Genes & development.

Treatment of Non‐Metastatic Muscle‐Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline

Yair Lotan, Roger Chou, Todd M Morgan, 2017, The Journal of urology.

INTRATUMORAL HETEROGENEITY OF ERBB2 AMPLIFICATION AND HER2 EXPRESSION IN MICROPAPILLARY UROTHELIAL CARCINOMA: MP48‐03

V. Reuter, S. Tickoo, S. Fine, 2017, Human pathology.

Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer

B. Taylor, A. Viale, M. Berger, 2016, Nature Genetics.

PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology

V. Reuter, S. Tickoo, S. Fine, 2019, The American journal of surgical pathology.

Somatic Copy Number Abnormalities and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial Tumors

E. V. Van Allen, T. Choueiri, J. Leow, 2015, PloS one.

Combination of a Novel Gene Expression Signature with a Clinical Nomogram Improves the Prediction of Survival in High-Risk Bladder Cancer

Franziska Michor, Markus Riester, B. Bochner, 2012, Clinical Cancer Research.

Urothelial carcinoma: Stem cells on the edge

E. Schaeffer, J. Rosenberg, D. Berman, 2009, Cancer and Metastasis Reviews.

Management of treatment-related toxicity with targeted therapies for renal cell carcinoma: evidence-based practice and best practices.

J. Rosenberg, J. Bellmunt, S. Morrissey, 2011, Hematology/oncology clinics of North America.

Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens.

S. Culine, T. Choueiri, J. Rosenberg, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.

E. Small, B. Rini, J. Rosenberg, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer.

T. Powles, C. Blank, J. Rosenberg, 2019, European urology.

Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens.

T. Powles, J. Rosenberg, B. Nelson, 2017, European urology.

Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.

S. Gabriel, E. Lander, M. Loda, 2014, Cancer discovery.

Lessons learned from exceptional responders

G. Iyer, J. Rosenberg, 2019, Expert Review of Precision Medicine and Drug Development.

A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor‐targeted therapies

E. V. Van Allen, S. Signoretti, T. Choueiri, 2016, Cancer.

Molecular targets on the horizon for kidney and urothelial cancer

B. Teh, J. Rosenberg, G. Tortora, 2013, Nature Reviews Clinical Oncology.

ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer

Qiang Li, Joaquim Bellmunt, Nadeem Riaz, 2018, Clinical Cancer Research.

Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study

J. Rosenberg, D. Petrylak, A. Necchi, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.

Keith T Flaherty, Paul S Meltzer, Maria J Merino, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Propensity-matched analysis of patient-reported outcomes for neoadjuvant chemotherapy prior to radical cystectomy

V. Laudone, B. Rapkin, B. Bochner, 2019, World Journal of Urology.

Exploring Patterns of Mitomycin C Use in Community Practice Urology

Steven L. Chang, J. Leow, Ye Wang, 2018, Urology practice.

Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear‐cell renal cell carcinoma receiving vascular endothelial growth factor‐targeted therapy

S. Signoretti, T. Choueiri, M. Atkins, 2010, BJU international.

MCL1 and DEDD Promote Urothelial Carcinoma Progression

W. Hahn, A. Letai, R. Beroukhim, 2019, Molecular Cancer Research.

Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial

I. Ostrovnaya, G. Iyer, H. Al-Ahmadie, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer.

C. Bourque, M. Berger, I. Ostrovnaya, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Systemic, perioperative management of muscle-invasive bladder cancer and future horizons

J. Rosenberg, S. Funt, 2017, Nature Reviews Clinical Oncology.

Elevating the Horizon: Emerging Molecular and Genomic Targets in the Treatment of Advanced Urothelial Carcinoma.

T. Powles, J. Rosenberg, R. Qin, 2015, Clinical genitourinary cancer.

Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle‐invasive bladder cancer

T. Powles, N. Agarwal, M. Galsky, 2015, Cancer.

Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward.

E. Messing, Y. Lotan, V. Margulis, 2015, Urologic oncology.

IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.

D. Maloney, J. Rosenberg, C. White, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Author Correction: High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade

P. Hegde, T. Powles, Z. Modrušan, 2021, Nature medicine.

Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy.

G. Sonpavde, W. Oh, M. Galsky, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Role of Aberrant VHL/HIF Pathway Elements in Predicting Clinical Outcome to Pazopanib Therapy in Patients with Metastatic Clear-Cell Renal Cell Carcinoma

S. Signoretti, T. Choueiri, J. Rosenberg, 2013, Clinical Cancer Research.

The Genitourinary Pathology Society Update on Classification of Variant Histologies, T1 Substaging, Molecular Taxonomy, and Immunotherapy and PD-L1 Testing Implications of Urothelial Cancers

J. Cheville, R. Shah, J. McKenney, 2021, Advances in anatomic pathology.

Inherited Germline Cancer Susceptibility Gene Variants in Individuals with Non–Muscle-Invasive Bladder Cancer

M. Berger, K. Offit, I. Ostrovnaya, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy

E. Small, B. Rini, J. Rosenberg, 2006, BJU international.

Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma.

I. Ostrovnaya, G. Iyer, M. Milowsky, 2020, European urology.

Prognostic Value of TERT Alterations, Mutational and Copy Number Alterations Burden in Urothelial Carcinoma.

M. Berger, V. Reuter, I. Ostrovnaya, 2017, European urology focus.

IMvigor210: updated analyses of first-line (1L) atezolizumab (atezo) in cisplatin (cis)-ineligible locally advanced/metastatic urothelial carcinoma (mUC)

M. Galsky, A. Balar, J. Rosenberg, 2016 .

Study EV-103: Update on durability results and long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma (la/mUC).

M. Milowsky, S. Srinivas, A. Balar, 2021 .

705MO Sitravatinib (sitra) in combination with nivolumab (nivo) demonstrates clinical activity in checkpoint inhibitor (CPI) naïve, platinum-experienced patients (pts) with advanced or metastatic urothelial carcinoma (UC)

J. Christensen, J. Rosenberg, D. Shaffer, 2020 .

Activity of second‐line chemotherapy in docetaxel‐refractory hormone‐refractory prostate cancer patients

M. Gross, V. Weinberg, E. Small, 2007, Cancer.

Hormonal therapy or external-beam radiation with brachytherapy and the risk of death from prostate cancer in men with intermediate risk prostate cancer.

A. D'Amico, Ming-Hui Chen, J. Rosenberg, 2012, Clinical genitourinary cancer.

Evaluation and significance of circulating epithelial Cells in hormone refractory prostate cancer patients Appendix 2

J. Rosenberg, 2008 .

A phase II trial of durvalumab and tremelimumab in metastatic, non‐urothelial carcinoma of the urinary tract

J. Chaim, I. Ostrovnaya, G. Iyer, 2020, Cancer medicine.

Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results.

P. Ascierto, B. Mellado, P. Sharma, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I evaluation of abiraterone acetate (CB7630), a 17 alpha hydroxylase C17,20-Lyase inhibitor in androgen-independent prostate cancer (AiPC)

E. Small, J. Rosenberg, C. Ryan, 2007 .

A randomized phase II study of ixabepilone (Ix) or mitoxantrone and prednisone (MP) in patients with taxane (T)-resistant hormone refractory prostate cancer (HRPC)

M. Gross, M. Michaelson, G. Wilding, 2005 .

Marker lesion study of oral FGFR inhibitor BGJ398 in patients with FGFR3-altered intermediate-risk nonmuscle-invasive bladder cancer.

I. Ostrovnaya, G. Iyer, B. Bochner, 2020 .

Study EV-103: Preliminary durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma.

M. Milowsky, S. Srinivas, J. Rosenberg, 2020 .

EV-103: Enfortumab vedotin plus pembrolizumab and/or chemotherapy for locally advanced or metastatic urothelial cancer.

J. Rosenberg, D. Petrylak, T. Flaig, 2019, Journal of Clinical Oncology.

Alliance A031501: Phase III randomized adjuvant study of MK-3475 (pembrolizumab) in muscle-invasive and locally advanced urothelial carcinoma (MIBC) (AMBASSADOR) versus observation.

Ronald C. Chen, G. Sonpavde, M. Morris, 2019, Journal of Clinical Oncology.

Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder Cancer.

C. Dinney, M. Milowsky, D. Bajorin, 2019, JAMA oncology.

Identification of Nine Genomic Regions of Amplification in Urothelial Carcinoma, Correlation with Stage, and Potential Prognostic and Therapeutic Value

D. Kwiatkowski, M. Riester, Chin-Lee Wu, 2013, PloS one.

FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder

M. Loda, P. Kantoff, L. Garraway, 2014, Cancer medicine.

FGFR 3 expression in primary and metastatic urothelial carcinoma of the bladder

M. Loda, P. Kantoff, L. Garraway, 2014 .

BAYOU: A phase II, randomized, multicenter, double-blind, study of durvalumab (D) in combination with olaparib (O) for the first-line treatment of platinum-ineligible patients with unresectable, stage IV urothelial carcinoma (UC).

D. Bajorin, S. Park, J. Rosenberg, 2022, Journal of Clinical Oncology.

Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors

C. Rudin, E. Schmidt, H. Pandha, 2023, Journal for ImmunoTherapy of Cancer.

Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial Carcinoma.

G. Pond, T. Choueiri, G. Sonpavde, 2016, The Journal of urology.

Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy.

I. Ostrovnaya, M. Milowsky, D. Bajorin, 2013, Journal of the National Cancer Institute.

Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU)

D. Bajorin, S. Park, J. Rosenberg, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical and Morphologic Characteristics of Fibroblast Growth Factor Receptor Inhibitor-Associated Retinopathy.

A. Drilon, M. Voss, G. Iyer, 2021, JAMA ophthalmology.

Developing Precision Medicine for Bladder Cancer.

G. Iyer, J. Rosenberg, Brendan J. Guercio, 2021, Hematology/oncology clinics of North America.

Reply by Authors.

P. D. Di Paolo, H. Vargas, B. Bochner, 2020, Journal of Urology.

The emerging role of antibody-drug conjugates in urothelial carcinoma

J. Rosenberg, Michael Lattanzi, 2020, Expert review of anticancer therapy.

LBA-17 MULTICENTER PROSPECTIVE PHASE II CLINICAL TRIAL OF GEMCITABINE AND CISPLATIN AS NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH HIGH-GRADE UPPER TRACT UROTHELIAL CARCINOMA

J. Coleman, D. Sjoberg, G. Iyer, 2019, Journal of Urology.

Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.

M. Harrison, E. Heath, A. Balar, 2021, The Lancet. Oncology.

Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors: An updated analysis of EV-201 Cohort 2.

M. Harrison, S. Park, E. Heath, 2021, Journal of Clinical Oncology.

Study EV-103: Durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma.

M. Milowsky, S. Srinivas, J. Rosenberg, 2020 .

Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma.

L. Garraway, E. V. Van Allen, E. Plimack, 2016, JAMA oncology.

Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes

G. Sonpavde, D. Potvin, M. Milowsky, 2018, Cancer.

Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients (pts) with muscle invasive bladder cancer (MIBC) who are cisplatin-ineligible.

S. Srinivas, J. Rosenberg, D. Petrylak, 2022, Journal of Clinical Oncology.

Quality of life, functioning, and symptoms in patients with previously treated locally advanced or metastatic urothelial carcinoma from EV-301: A randomized phase 3 trial of enfortumab vedotin versus chemotherapy.

T. Powles, G. Sonpavde, J. Rosenberg, 2021 .

EV-103: Initial results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma

M. Milowsky, S. Srinivas, J. Rosenberg, 2019, Annals of Oncology.

Expression Levels of DNA Damage Repair Proteins Are Associated With Overall Survival in Platinum-Treated Advanced Urothelial Carcinoma.

M. Loda, P. Kantoff, T. Choueiri, 2016, Clinical genitourinary cancer.

Defining “platinum-ineligible” patients with metastatic urothelial cancer (mUC).

E. Plimack, G. Sonpavde, M. Galsky, 2019, Journal of Clinical Oncology.

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

C. Brennan, M. Ladanyi, M. Berger, 2019, Nature Genetics.

Evaluation and significance of circulating epithelial cells in patients with hormone‐refractory prostate cancer

E. Small, J. Rosenberg, John W. Park, 2007, BJU international.

CD8+ T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy

P. Hegde, Z. Modrušan, James Ziai, 2022, Cell reports. Medicine.

Gene Expression Analysis of Circulating Hormone Refractory Prostate Cancer Micrometastases

J. Rosenberg, 2007 .

Rapid Inhibition of Cancer Cell Growth Induced by Lentiviral Delivery and Expression of Mutant-Template Telomerase RNA and Anti-telomerase Short-Interfering RNA

E. Blackburn, J. Rosenberg, Shang Li, 2004, Cancer Research.

Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer.

P. Kantoff, T. Choueiri, G. Sonpavde, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort†: Under the Auspices of the EAU-ESMO Guidelines Committees.

M. Babjuk, T. D. de Reijke, S. Culine, 2019, European urology.

Rapid inhibition of cancer cell growth induced by lentiviral expression of mutant-template telomerase RNA constructs and anti-telomerase siRNA

E. Blackburn, J. Rosenberg, Shang Li, 2004 .

Circulating biomarkers to guide systemic therapy for urothelial carcinoma.

E. Plimack, J. Rosenberg, Philip H. Abbosh, 2016, Urologic oncology.

Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients

Julie L. Yang, N. Socci, V. Seshan, 2021, Genome medicine.

Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors.

G. Pond, T. Powles, T. Choueiri, 2020, The Journal of urology.

Novel therapies in urothelial carcinoma: a biomarker-driven approach

J. Rosenberg, G. Iyer, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Molecular Signature of Response to Pazopanib Salvage Therapy for Urothelial Carcinoma.

M. Berger, G. Iyer, D. Solit, 2016, Clinical Genitourinary Cancer.

Phase I Study of Everolimus in Combination with Gemcitabine and Split-Dose Cisplatin in Advanced Urothelial Carcinoma

I. Ostrovnaya, M. Voss, M. Milowsky, 2016, Bladder cancer.

Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinoma.

G. Pond, P. Albers, T. Choueiri, 2015, Clinical genitourinary cancer.

Optimal Treatment for Metastatic Bladder Cancer

J. Rosenberg, E. Carballido, 2014, Current Oncology Reports.

Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle‐invasive bladder cancer

M. Mazumdar, T. Powles, E. Plimack, 2019, Cancer.

Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.

N. Schultz, M. Berger, G. Iyer, 2019, European urology.

The evolving understanding of microRNA in bladder cancer.

S. Yeh, J. Rosenberg, J. Bellmunt, 2014, Urologic oncology.

Infigratinib and treatment response in advanced/unresectable or metastatic urothelial carcinoma in first-line and later-line treatment settings.

M. Galsky, D. Bajorin, J. Rosenberg, 2020 .

Genomic Biomarkers for the Prediction of Stage and Prognosis of Upper Tract Urothelial Carcinoma.

M. Berger, V. Reuter, I. Ostrovnaya, 2016, The Journal of urology.

Actionable mutations in muscle-invasive bladder cancer

J. Rosenberg, R. Bambury, 2013, Current opinion in urology.

A Phase I Study of a 2-Day Lapatinib Chemosensitization Pulse Preceding Nanoparticle Albumin-Bound Paclitaxel for Advanced Solid Malignancies

Benjamin M Yeh, Lee-may Chen, Yong Huang, 2009, Clinical Cancer Research.

Imaging , Diagnosis , Prognosis A Phase I Study of a 2-Day Lapatinib Chemosensitization Pulse Preceding Nanoparticle Albumin-Bound Paclitaxel for Advanced Solid Malignancies

N. Hylton, M. Moasser, B. Yeh, 2009 .

Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance)

E. Plimack, M. Morris, D. Bajorin, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dermatologic Infections in Cancer Patients Treated with Checkpoint Inhibitors.

M. Lacouture, J. Rosenberg, M. Postow, 2021, Journal of the American Academy of Dermatology.

Intermittent chemotherapy (ICh) for metastatic castration-resistant prostate cancer (mCRPC): Results of a prospective randomized phase II trial of the DoD Prostate Cancer Clinical Trials Consortium.

V. Weinberg, C. Higano, E. Small, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

44 – Cancer of the Bladder

M. Zelefsky, E. Small, J. Rosenberg, 2010 .

IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC).

T. Powles, P. Albers, J. Gschwend, 2020 .

Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1.

T. Powles, M. Galsky, D. Bajorin, 2016 .

Updated results from the enfortumab vedotin phase 1 (EV-101) study in patients with metastatic urothelial cancer (mUC).

David C. Smith, E. Plimack, M. Milowsky, 2018 .

NECTIN4 Heterogeneity and Molecular Diversity in Bladder Cancers: Deconstructing the Activity of An Antibody–Drug Conjugate

J. Rosenberg, M. Teo, 2021, Clinical Cancer Research.

852PDAtezolizumab (atezo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Post-progression outcomes from the phase 2 IMvigor210 study

J. Rosenberg, D. Petrylak, A. Necchi, 2017 .

Nomogram to assess benefit of new over historical agents as salvage therapy for metastatic urothelial carcinoma (mUC) in non-randomized trials: Effect of atezolizumab on 12-month survival.

G. Pond, T. Choueiri, G. Sonpavde, 2017 .

A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer.

E. Small, G. Bubley, B. Rini, 2007, Clinical genitourinary cancer.

Pathological and oncological outcomes in patients with sarcomatoid differentiation undergoing cystectomy

D. Sjoberg, G. Iyer, H. Al-Ahmadie, 2021, BJU international.

Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma

V. Reuter, I. Ostrovnaya, S. Tickoo, 2021, British Journal of Cancer.

Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect.

F. Montorsi, A. Salonia, N. Agarwal, 2019, European urology.

Refining existing knowledge and management of bladder cancer

J. Rosenberg, M. Teo, 2018, Nature Reviews Urology.

Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials.

F. Montorsi, N. Agarwal, E. Plimack, 2019, European urology oncology.

Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial Carcinoma

A. Hakimi, H. Vargas, J. Coleman, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

W. Oyen, M. Babjuk, S. Culine, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Rituximab therapy in Waldenstrom's macroglobulinemia: preliminary evidence of clinical activity.

J. Byrd, J. Rosenberg, W. Velasquez, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Targeting angiogenesis in bladder cancer

J. Rosenberg, A. Elfiky, 2009, Current oncology reports.

Imaging , Diagnosis , Prognosis Combination of a Novel Gene Expression Signature with a Clinical Nomogram Improves the Prediction of Survival in High-Risk Bladder Cancer

B. Bochner, M. Riester, J. Rosenberg, 2012 .

Bladder Cancer Nomogram Improves the Prediction of Survival in High-Risk Combination of a Novel Gene Expression Signature with a Clinical

B. Bochner, J. Rosenberg, F. Michor, 2012 .

Clinical outcome of taxane-resistant (TR) hormone refractory prostate cancer (HRPC) patients (pts) treated with subsequent chemotherapy (ixabepilone (Ix) or mitoxantrone/prednisone (MP).

M. Michaelson, G. Wilding, V. Weinberg, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase Ib KEYNOTE-200: A study of an intravenously delivered oncolytic virus, coxsackievirus A21 in combination with pembrolizumab in advanced NSCLC and bladder cancer patients.

C. Rudin, H. Pandha, D. Gerber, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety and preliminary efficacy of rogaratinib in combination with atezolizumab in a phase Ib/II study (FORT-2) of first-line treatment in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (UC) and FGFR mRNA overexpression.

J. Rosenberg, V. Zagonel, A. Necchi, 2020 .

Novel Genetic Subtypes of Urothelial Carcinoma With Differential Outcomes on Immune Checkpoint Blockade

V. Seshan, Chen Zhao, I. Ostrovnaya, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical Trials and Emerging Therapeutic Strategies in Bladder Cancer

J. Rosenberg, R. Bambury, R. Sims, 2015 .

Pharmacokinetic analysis of serum concentrations of the chimeric anti-CD20 antibody IDEC-C2B8 in patients with relapsed B cell lymphoma

D. Maloney, J. Rosenberg, C. White, 1995 .

Personalized therapy for urothelial cancer: review of the clinical evidence.

J. Rosenberg, E. Guancial, Dipanjan Chowdhury, 2011, Clinical investigation.

Beyond Docetaxel: Emerging Agents in the Treatment of Advanced Prostate Cancer

J. Rosenberg, 2010 .

A pilot dose‐escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer

E. Small, J. Rosenberg, I. Goldfine, 2008, BJU international.

PD47-07 UTILITY OF ROUTINE PREOPERATIVE 18-FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY IN IDENTIFYING PATHOLOGIC LYMPH NODE METASTASES AT RADICAL CYSTECTOMY

P. D. Di Paolo, H. Vargas, B. Bochner, 2019, Journal of Urology.

Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus.

J. Rosenberg, D. Wofsy, M. Totoritis, 2001, The Journal of rheumatology.

Patients with metastatic renal cell carcinoma with long-term disease-free survival after treatment with sunitinib and resection of residual metastases.

B. Rini, J. Rosenberg, I. Chen, 2006, Clinical genitourinary cancer.

Second-line chemotherapy for hormone-refractory prostate cancer: has the time come?

E. Small, J. Rosenberg, 2004, Clinical prostate cancer.

DNA damage repair and response (DDR) gene alterations (alt) and response to PD1/PDL1 blockade in platinum-treated metastatic urothelial carcinoma (mUC).

J. Wolchok, J. Chaim, I. Ostrovnaya, 2017 .

Correlation of DNA damage response (DDR) gene alterations with response to neoadjuvant (neo) dose-dense gemcitabine and cisplatin (ddGC) in urothelial carcinoma (UC).

I. Ostrovnaya, G. Iyer, M. Milowsky, 2016 .

SnapShot: Bladder Cancer.

J. Rosenberg, M. Knowles, C. Hurst, 2018, Cancer cell.

First-line treatment and prognostic factors of metastatic bladder cancer for platinum-eligible patients.

D. Bajorin, J. Rosenberg, W. Abida, 2015, Hematology/oncology clinics of North America.

Association of somatic ERCC2 mutations with cisplatin sensitivity in muscle-invasive urothelial carcinoma.

S. Gabriel, G. Getz, P. Kantoff, 2014 .

Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer

P. Kantoff, G. Bubley, J. Rosenberg, 2015, Cancer.

Development of a Prediction Tool for Exclusive Locoregional Recurrence After Radical Cystectomy in Patients With Muscle‐Invasive Bladder Cancer

G. Pond, F. Montorsi, N. Agarwal, 2019, Clinical genitourinary cancer.

Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population

G. Pond, T. Powles, N. Agarwal, 2018, Clinical genitourinary cancer.

Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).

L. Mariani, T. Powles, N. Agarwal, 2017, European urology.

Clinical-pathologic stage discrepancy in patients with bladder cancer treated with radical cystectomy: Associations with clinical variables and survival.

A. Jemal, A. Kibel, A. Zietman, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Recent progress and pitfalls in testing novel agents in castration-resistant prostate cancer.

T. Choueiri, J. Rosenberg, J. Bellmunt, 2009, European urology.

Pembrolizumab (pembro) in combination with gemcitabine (Gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIBC): A multicenter phase 2 trial.

N. Sanfilippo, M. Milowsky, S. Taneja, 2021 .

Abstract LB-316: The landscape of actionable genomic lesions in small cell bladder cancer

B. Taylor, S. Asthana, H. Al-Ahmadie, 2014 .

CD274 (PD-L1) Copy Number Changes (Gain) & Response to Immune Checkpoint Blockade Therapy in Carcinomas of the Urinary Tract.

J. Cheville, M. Ladanyi, V. Reuter, 2021, Bladder cancer.

Study EV-103 cohort L: Evaluating perioperative enfortumab vedotin monotherapy in cis-ineligible muscle invasive bladder cancer (MIBC) (trial in progress).

S. Srinivas, J. Rosenberg, P. O’Donnell, 2022, Journal of Clinical Oncology.

Clinical pharmacology of the antibody-drug conjugate enfortumab vedotin in advanced urothelial carcinoma and other malignant solid tumors.

P. Bonate, J. Rosenberg, T. Kadokura, 2022, Journal of Clinical Oncology.

Summary of the 6th Annual Bladder Cancer Think Tank: new directions in urologic research.

Y. Lotan, M. Galsky, B. Bochner, 2013, Urologic oncology.

Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma.

D. Lamm, G. Sonpavde, M. Galsky, 2017, Journal for immunotherapy of cancer.

Treatment Decision Making in Patients with Bladder Cancer

A. Kibel, J. Rosenberg, K. Loughlin, 2015, Bladder cancer.

Mismatch repair (MMR) detection in urothelial carcinoma (UC) and correlation with immune checkpoint blockade (ICB) response.

G. Iyer, H. Al-Ahmadie, D. Bajorin, 2017 .

Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy.

N. Socci, B. Taylor, N. Schultz, 2014, Cancer discovery.

CALGB 90207: Phase II trial of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma (TCC).

D. Bajorin, E. Small, J. Rosenberg, 2006, Journal of Clinical Oncology.

Targeting nectin-4 by antibody-drug conjugates for the treatment of urothelial carcinoma

J. Rosenberg, Jeffrey L. Wong, 2021, Expert opinion on biological therapy.

A phase I study of enfortumab vedotin (ASG-22CE; ASG-22ME): Updated analysis of patients with metastatic urothelial cancer.

David C. Smith, J. Lang, E. Heath, 2017 .

Cancer predisposing germline mutations in patients (pts) with urothelial cancer (UC) of the renal pelvis (R-P), ureter (U) and bladder (B).

K. Offit, A. Hakimi, J. Coleman, 2017 .

Squamous-cell carcinoma variant histology (SCC-VH) in muscle-invasive bladder cancer (MIBC): A comprehensive clinical, genomic, and therapeutic assessment from multiple datasets.

F. Montorsi, A. Salonia, N. Agarwal, 2019, Journal of Clinical Oncology.

Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207.

D. Bajorin, E. Small, J. Rosenberg, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Loss of Sh3gl2/endophilin A1 is a common event in urothelial carcinoma that promotes malignant behavior.

P. Park, R. Matusik, J. Rosenberg, 2013, Neoplasia.

Re: Floris H. Groenendijk, Jeroen de Jong, Elisabeth E. Fransen van de Putte, et al. ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.01.014.

L. Garraway, E. V. Van Allen, J. Rosenberg, 2015, European urology.

Critical analysis of contemporary clinical research in muscle‐invasive and metastatic urothelial cancer

G. Sonpavde, M. Galsky, J. Rosenberg, 2013, Cancer.

Unfavourable cancer specific survival after neoadjuvant chemotherapy and radical cystectomy in bladder cancer patients with squamous-cell variant: A multi-institutional study

F. Montorsi, A. Salonia, N. Agarwal, 2021 .

Gemcitabine-cisplatin (GC) plus radical cystectomy-pelvic lymph node dissection (RC-PLND) for patients (pts) with muscle-invasive bladder cancer (MIBC): Assessing impacts of neoadjuvant chemotherapy (NAC) and the PLND.

I. Ostrovnaya, B. Bochner, D. Bajorin, 2014 .

Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin

M. Lacouture, J. Rosenberg, P. O’Donnell, 2022, The oncologist.

698P Analysis of hard-to-treat subgroups from EV-301: A phase III trial of enfortumab vedotin (EV) vs chemotherapy for previously treated advanced urothelial carcinoma

T. Powles, G. Sonpavde, J. Rosenberg, 2021, Annals of Oncology.

746P EV-201: Long-term results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and PD-1/PD-L1 inhibitors

M. Galsky, E. Heath, A. Balar, 2020 .

Correlation of peripheral and intratumoral T-cell receptor (TCR) clonality with clinical outcomes in patients with metastatic urothelial cancer (mUC) treated with atezolizumab.

M. Vignali, G. Iyer, D. Bajorin, 2016 .

Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: American Urological Association/American Society of Clinical Oncology/American Society for Radiation Oncology/Society of Urologic Oncology Clinical Practice Guideline Summary.

R. Chou, Y. Lotan, Sam S. Chang, 2017, Journal of oncology practice.

Adherence to cisplatin-based regimens prescription in "fit" patients fulfilling platinum eligibility criteria. Impact on outcomes: a retrospective international study of invasive/advanced cancer of the urothelium (RISC) analysis

T. Powles, N. Agarwal, C. Sternberg, 2016 .

Patterns of chemotherapy utilization in metastatic urothelial cancer (mUC): analysis from the retrospective international study of invasive/advanced cancer of the urothelium (RISC) database

T. Powles, N. Agarwal, C. Sternberg, 2016 .

Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer

G. Getz, S. Carter, L. Garraway, 2017, Nature Communications.

Comparative effectiveness of gemcitabine plus cisplatin (GC) versus methotrexate, vinblastine, doxorubicin, plus cisplatin (MVAC) as neoadjuvant therapy for muscle-invasive bladder cancer (MIBC).

T. Powles, N. Agarwal, M. Galsky, 2014 .

The Cost of Enfortumab Vedotin Wastage Due to Vial Size—A Real-World Analysis

J. Rosenberg, A. Regazzi, M. Sarfaty, 2021, Cancers.

A phase 3 study to evaluate enfortumab vedotin (EV) versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC): EV-301, a trial-in-progress

T. Powles, G. Sonpavde, J. Rosenberg, 2019, European Urology Supplements.

Mature results from EV-101: A phase I study of enfortumab vedotin in patients with metastatic urothelial cancer (mUC).

David C. Smith, E. Plimack, M. Milowsky, 2019, Journal of Clinical Oncology.

Interim analysis of a phase I dose escalation trial of ASG-22CE (ASG-22ME; enfortumab vedotin), an antibody drug conjugate (ADC), in patients (Pts) with metastatic urothelial cancer (mUC)

David C. Smith, J. Lang, E. Heath, 2016 .

Neoadjuvant immunotherapy for prostate cancer with GM-CSF and tumor infiltration by antigen presenting cells

P. Carroll, E. Small, J. Rosenberg, 2008 .

Nivolumab monotherapy in metastatic urothelial carcinoma: Longer-term efficacy and safety results from the CheckMate 032 study.

D. Jäger, P. Sharma, P. Ott, 2018 .

Radical cystectomy or bladder preservation with radiochemotherapy in elderly patients with muscle-invasive bladder cancer: Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators

T. Powles, M. Galsky, M. Milowsky, 2017, Acta oncologica.

Atezolizumab (atezo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Outcomes by prior therapy.

T. Powles, J. Rosenberg, A. Necchi, 2017 .

Improved prognostic classification of patients receiving salvage systemic therapy for advanced urothelial carcinoma.

G. Pond, P. Albers, T. Choueiri, 2015 .

EV-201 Cohort 2: Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors.

M. Harrison, S. Park, E. Heath, 2021 .

Japanese subgroup analysis of EV‐301: An open‐label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma

T. Powles, J. Rosenberg, T. Kojima, 2022, Cancer medicine.

The Borealis-2 clinical trial: A randomized phase II study of OGX-427 plus docetaxel versus docetaxel alone in relapsed/refractory metastatic urothelial cancer.

T. Choueiri, M. Regan, J. Rosenberg, 2013 .

A phase II multicenter study of neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) chemotherapy with pegfilgrastim support in patients (pts) muscle-invasive urothelial cancer (MIUC): Safety, pathologic, radiologic, and molecular correlates.

S. Signoretti, G. Bubley, G. Steele, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Metastatic Cutaneous Squamous Cell Carcinoma of the Colon Presenting as Transfusion-Dependent Hematochezia

C. Hajdu, J. Rosenberg, G. Gurvits, 2020, ACG case reports journal.

Activity of ketoconazole after taxane‐based chemotherapy in castration‐resistant prostate cancer

P. Kantoff, W. Oh, M. Regan, 2009, BJU international.

Checkpoint Inhibitors in Urothelial Carcinoma-Future Directions and Biomarker Selection.

M. Milowsky, J. Rosenberg, J. Meeks, 2023, European urology.

Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study.

Michael B Atkins, P. Kantoff, S. Signoretti, 2013, The Lancet. Oncology.

Ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer refractory to docetaxel-based therapy: A phase II study of the DOD Prostate Cancer Clinical Trials Consortium.

D. Smith, V. Weinberg, E. Small, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine.

Joaquim Bellmunt, T. Choueiri, J. Rosenberg, 2012, European journal of cancer.

Phase 2 study of the pan-isoform PI3 kinase inhibitor BKM120 in metastatic urothelial carcinoma patients.

M. Berger, G. Iyer, H. Al-Ahmadie, 2015 .

Sunitinib therapy for patients (pts) with metastatic renal cell carcinoma (mRCC): Updated results of two phase II trials and prognostic factor analysis for survival

R. Motzer, M. Michaelson, B. Redman, 2007 .

Split-dose cisplatin as an alternative to every-3-week dosing when using cisplatin/gemcitabine to treat advanced urothelial cancer.

I. Ostrovnaya, G. Iyer, D. Bajorin, 2015 .

Targeting ERBB2 mutations in urothelial carcinoma.

M. Berger, G. Iyer, H. Al-Ahmadie, 2017 .

MP06-01 INCIDENCE AND IMPACT OF VENOUS THROMBOEMBOLISM IN RADICAL CYSTECTOMY PATIENTS UNDERGOING PRE-OPERATIVE CHEMOTHERAPY FOR MUSCLE-INVASIVE BLADDER CANCER

A. Vickers, D. Sjoberg, B. Bochner, 2016 .

Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy.

S. Culine, T. Choueiri, J. Rosenberg, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

2012 Annual Report

S. Seo, H. McArthur, J. Rosenberg, 2012 .

699P Atezolizumab monotherapy in cisplatin-ineligible patients with previously untreated metastatic urothelial carcinoma: 5-year response and survival analysis from the phase II IMvigor210 study (cohort 1)

M. Galsky, S. Srinivas, A. Balar, 2021, Annals of Oncology.

Neoadjuvant atezolizumab (A) with gemcitabine and cisplatin (GC) in patients (pts) with muscle-invasive bladder cancer (MIBC): A multicenter, single-arm, phase 2 trial.

I. Ostrovnaya, G. Iyer, H. Al-Ahmadie, 2021 .

Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

M. Milowsky, S. Srinivas, J. Rosenberg, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Enfortumab Vedotin in Advanced Urothelial Carcinoma. Reply.

T. Powles, J. Rosenberg, D. Petrylak, 2021, New England Journal of Medicine.

Infigratinib in upper tract urothelial carcinoma vs urothelial carcinoma of the bladder and association with comprehensive genomic profiling/cell-free DNA results.

M. Galsky, D. Bajorin, J. Rosenberg, 2019, Journal of Clinical Oncology.

Polygenic risk for skin autoimmunity impacts immune checkpoint blockade in bladder cancer

T. Powles, C. Hammer, I. Mellman, 2019, Proceedings of the National Academy of Sciences.

Atezolizumab (atezo) in platinum (plat)-treated locally advanced/metastatic urothelial carcinoma (mUC): Updated OS, safety and biomarkers from the Ph II IMvigor210 study

T. Powles, J. Rosenberg, A. Necchi, 2016 .

MP88-13 MUTATIONAL LANDSCAPE OF PRIMARY BLADDER AND URACHAL ADENOCARCINOMA

M. Berger, G. Iyer, H. Al-Ahmadie, 2016 .

Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study.

G. Pond, T. Powles, N. Agarwal, 2017, European Urology Focus.

Phase II trial of sunitinib in bevacizumab-refractory metastatic renal cell carcinoma (mRCC): Updated results and analysis of circulating biomarkers

M. Michaelson, J. Sosman, B. Rini, 2007 .

Abstract 2969: Progress in The Cancer Genome Atlas bladder cancer project

Joshua M. Stuart, Michael C. Ryan, Jeffrey S. Damrauer, 2015 .

MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy in patients (pts) with metastatic urothelial cancer (mUC; Alliance A032001).

M. Morris, J. Rosenberg, K. Ballman, 2023, Journal of Clinical Oncology.

Durable clinical benefit from combination ipilimumab (IPI) and nivolumab (NIVO) in anti-PD-1 therapy resistant, platinum resistant metastatic urothelial carcinoma (mUC).

E. Ziv, J. Wolchok, G. Iyer, 2019, Journal of Clinical Oncology.

Neoadjuvant nivolumab (N) +/- ipilimumab (I) in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC).

I. Ostrovnaya, G. Iyer, H. Al-Ahmadie, 2022, Journal of Clinical Oncology.

Erratum to: Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma

D. Lamm, G. Sonpavde, M. Galsky, 2017, Journal of Immunotherapy for Cancer.

EV-301: Phase III study to evaluate enfortumab vedotin (EV) versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC).

T. Powles, G. Sonpavde, J. Rosenberg, 2019, Journal of Clinical Oncology.

Reply to O. Dizdar et al

M. Galsky, J. Rosenberg, N. Hahn, 2011 .

Long-term outcomes in elderly patients (pts) from IMvigor210: Atezolizumab (atezo) in metastatic urothelial cancer (mUC).

A. Balar, J. Rosenberg, D. Petrylak, 2019, Journal of Clinical Oncology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .

Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma.

S. Gabriel, G. Getz, P. Kantoff, 2014, Cancer discovery.

Defining the DNA damage repair (DDR) genomic landscape of urothelial carcinoma of the bladder (UCB).

N. Schultz, M. Berger, G. Iyer, 2018 .

Pre-operative chemotherapy (ctx) in plasmacytoid urothelial carcinoma (PUC).

I. Ostrovnaya, G. Iyer, H. Al-Ahmadie, 2018 .

Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis of randomized clinical trials.

T. Choueiri, G. Sonpavde, M. Galsky, 2013, Critical reviews in oncology/hematology.

First-line treatment and prognostic factors of metastatic bladder cancer for platinum-eligible patients.

D. Bajorin, J. Rosenberg, W. Abida, 2015, Hematology/oncology clinics of North America.

Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear‐cell renal cell carcinoma receiving vascular endothelial growth factor‐targeted therapy

S. Signoretti, T. Choueiri, M. Atkins, 2010, BJU international.

Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study.

P. Kantoff, S. Signoretti, T. Choueiri, 2013, The Lancet. Oncology.

Prostate cancer update

E. Small, J. Rosenberg, 2003, Current opinion in oncology.

A phase II and biomarker study (MET111644) of the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Final efficacy, safety, and PD results.

W Marston Linehan, W. Linehan, R. Srinivasan, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comprehensive molecular characterization of urothelial bladder carcinoma

Evan O. Paull, Joshua M. Stuart, Richard A. Moore, 2014, Nature.

A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma

V. Weinberg, E. Small, J. Rosenberg, 2011, Cancer.

A multifactorial model of T cell expansion and durable clinical benefit in response to a PD-L1 inhibitor

Mark D. M. Leiserson, C. Borgs, J. Chayes, 2017, bioRxiv.

Somatic copy number abnormalities (SCNAs) and mutations in PI3K/AKT pathway as prognostic factors for overall survival (OS) in platinum-treated locally advanced or metastatic urothelial tumors.

J. Leow, J. Rosenberg, J. Bellmunt, 2014 .

NEXT GENERATION SEQUENCING OF UROTHELIAL BLADDER CANCER: MEMORIAL SLOAN KETTERING CANCER CENTER EXPERIENCE IN 454 PATIENTS: MP54‐04

M. Berger, I. Ostrovnaya, G. Iyer, 2018 .